{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:57:23Z","timestamp":1770782243279,"version":"3.50.0"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia A and hemophilia B are rare genetic disorders characterized by low plasma levels of coagulation factor VIII or factor IX, resulting in a bleeding tendency with a clinical severity proportional to the degree of the clotting factor deficiency. Although rare, hemophilia patients can paradoxically experience thrombotic events that complicate the clinical picture and the management by physicians operating at hemophilia treatment centers. Such thromboembolic complications, which can involve either the arterial or the venous districts, recognize various causes, including aging (due to the progress of care during the last three decades) and inherited and acquired (treatment-related) risk factors. These determinants often interact with each other to increase patients' susceptibility to thrombosis. In this narrative review, we summarize the current knowledge on the mechanisms, clinical presentation, and management of thrombotic complications in hemophilia patients.<\/jats:p>","DOI":"10.1055\/a-2603-0344","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T19:11:42Z","timestamp":1746731502000},"page":"164-173","source":"Crossref","is-referenced-by-count":0,"title":["Thrombotic Complications in Hemophilia: An Intricate Conundrum"],"prefix":"10.1055","volume":"52","author":[{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[{"name":"North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico and University of Milan, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2013from royal genes to gene therapy","volume":"344","author":"P M Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"M Franchini","year":"2013","journal-title":"Blood Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"M Franchini","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1055\/s-0042-1756188","article-title":"The more recent history of hemophilia treatment","volume":"48","author":"M Franchini","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"P M Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.2010.03899.x","article-title":"Inhibitors of propagation of coagulation (factors VIII, IX and XI): A review of current therapeutic practice","volume":"72","author":"M Franchini","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/cer-2021-0120","article-title":"Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data","volume":"10","author":"I Faghmous","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bjh.15745","article-title":"Haemophilia and ageing","volume":"184","author":"S Shapiro","year":"2019","journal-title":"Br J Haematol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2516.2009.01987.x","article-title":"Co-morbidity in the ageing haemophilia patient: The down side of increased life expectancy","volume":"15","author":"E P Mauser-Bunschoten","year":"2009","journal-title":"Haemophilia"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40266-017-0500-8","article-title":"Management of hemophilia in older patients","volume":"34","author":"M Franchini","year":"2017","journal-title":"Drugs Aging"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2141.2009.08005.x","article-title":"Co-morbidities and quality of life in elderly persons with haemophilia","volume":"148","author":"M Franchini","year":"2010","journal-title":"Br J Haematol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/diagnostics14030286","article-title":"Thrombotic disease in hemophilic patients: Is this a paradox in a state of hypocoagulability?","volume":"14","author":"O V Badulescu","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.18085","article-title":"Cardiovascular disease in hereditary haemophilia: The challenges of longevity","volume":"197","author":"S Shapiro","year":"2022","journal-title":"Br J Haematol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.rpth.2022.100007","article-title":"Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review","volume":"7","author":"A D Shapiro","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e33298","DOI":"10.1097\/MD.0000000000033298","article-title":"Acute coronary syndrome management in hemophiliacs: How to maintain balance?: A review","volume":"102","author":"H Chen","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0030-1248728","article-title":"The management of cardiovascular diseases in patients with hemophilia","volume":"36","author":"A Coppola","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2022.282407","article-title":"How we manage cardiovascular disease in patients with hemophilia","volume":"108","author":"M Franchini","year":"2023","journal-title":"Haematologica"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2013.05.007","article-title":"Management of cardiovascular disease in haemophilia","volume":"132","author":"G Cayla","year":"2013","journal-title":"Thromb Res"},{"issue":"10","key":"ref19","first-page":"1072","article-title":"Current therapeutic approach to acute myocardial infarction in patients with congenital hemophilia","volume":"11","author":"M C Badescu","year":"2021","journal-title":"Life (Basel)"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/hae.12525","article-title":"Management of atrial fibrillation in people with haemophilia\u2013a consensus view by the ADVANCE Working Group","volume":"20","author":"R E Schutgens","year":"2014","journal-title":"Haemophilia"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hae.14674","article-title":"Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group","volume":"29","author":"R Klamroth","year":"2023","journal-title":"Haemophilia"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jtha.2024.10.033","article-title":"Use of antithrombotic therapy in patients with hemophilia: A selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document","volume":"23","author":"M Escobar","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: An EHA-ISTH-EAHAD-ESO clinical practice guidance","volume":"7","author":"R EG Schutgens","year":"2023","journal-title":"HemaSphere"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hae.12445","article-title":"Atrial fibrillation in patients with haemophilia: A cross-sectional evaluation in Europe","volume":"20","author":"R EG Schutgens","year":"2014","journal-title":"Haemophilia"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/bloodadvances.2021005260","article-title":"Reduced cardiovascular morbidity in patients with hemophilia: Results of a 5-year multinational prospective study","volume":"6","author":"P Van Der Valk","year":"2022","journal-title":"Blood Adv"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14656566.2012.656591","article-title":"Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia","volume":"13","author":"P M Mannucci","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists","volume":"15","author":"M LY de Koning","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0040-1718410","article-title":"Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: Results from the French Registry","volume":"121","author":"B Guillet","year":"2021","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1055\/s-0039-1698756","article-title":"Catheter ablation for atrial fibrillation in patients with hemophilia or von Willebrand disease","volume":"3","author":"P R van der Valk","year":"2019","journal-title":"TH Open"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11239-020-02097-5","article-title":"Left atrial appendage closure: A balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation","volume":"50","author":"M Toselli","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2021.08.001","article-title":"Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia","volume":"206","author":"M Y Lim","year":"2021","journal-title":"Thromb Res"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10557-021-07232-9","article-title":"Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"37","author":"W Xu","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"04","key":"ref33","first-page":"2157","article-title":"Comparing safety and efficacy of dabigatran and factor Xa inhibitors for stroke prevention in hemophiliacs with non-valvular atrial fibrillation","volume":"12","author":"S Khan","year":"2019","journal-title":"J Atr Fibrillation"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/pds.5317","article-title":"Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies","volume":"30","author":"H A van den Ham","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"36","key":"ref35","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"I C Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.001","article-title":"Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: Systematic review, meta-analysis and meta-regression","volume":"79","author":"D Sagris","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/hae.12189","article-title":"Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - An assessment by the ADVANCE Working Group","volume":"19","author":"P Staritz","year":"2013","journal-title":"Haemophilia"},{"issue":"03","key":"ref38","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"J S Lawton","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"ref39","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"M Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jacc.2004.04.034","article-title":"Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials","volume":"44","author":"P Agostoni","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"S 03","key":"ref41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2516.2010.02262.x","article-title":"Cardiovascular disease in haemophilia patients: A contemporary issue","volume":"16","author":"P M Mannucci","year":"2010","journal-title":"Haemophilia"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hae.14963","article-title":"Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome","volume":"30","author":"P Agosti","year":"2024","journal-title":"Haemophilia"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1097\/HS9.0000000000000918","article-title":"Thrombosis and hemophilia: Little more evidence, much more guidance","volume":"7","author":"C Hermans","year":"2023","journal-title":"HemaSphere"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/hae.14906","article-title":"Management strategies in persons with inherited haemophilia requiring antithrombotic therapy: A scoping review","volume":"30","author":"K Uminski","year":"2024","journal-title":"Haemophilia"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11239-013-0943-7","article-title":"Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B","volume":"37","author":"A Girolami","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"S 06","key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"P M Rothwell","year":"2016","journal-title":"Lancet"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"E Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.thromres.2017.05.038","article-title":"Modifiers of clinical phenotype in severe congenital hemophilia","volume":"156","author":"M Franchini","year":"2017","journal-title":"Thromb Res"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0029-1222609","article-title":"Interpatient phenotypic inconsistency in severe congenital hemophilia: A systematic review of the role of inherited thrombophilia","volume":"35","author":"M Franchini","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613824","article-title":"Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A","volume":"83","author":"D H Lee","year":"2000","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-0037-1615679","article-title":"Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors","volume":"85","author":"C Escuriola Ettingshausen","year":"2001","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref53","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3324\/haematol.11161","article-title":"Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children\u2013results of a multicenter studys","volume":"92","author":"K Kurnik","year":"2007","journal-title":"Haematologica"},{"issue":"03","key":"ref54","first-page":"279","article-title":"The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors","volume":"87","author":"E F Tizzano","year":"2002","journal-title":"Haematologica"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1538-7836.2008.03001.x","article-title":"Validation of a composite score for clinical severity of hemophilia","volume":"6","author":"S Schulman","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1055\/s-0038-1649922","article-title":"Low prevalence of the factor V Leiden mutation among \u201csevere\u201d hemophiliacs with a \u201cmilder\u201d bleeding diathesis","volume":"74","author":"A A Arbini","year":"1995","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2516.1996.tb00011.x","article-title":"Association of severe haemophilia A and factor V Leiden: Report of three cases","volume":"2","author":"V R Arruda","year":"1996","journal-title":"Haemophilia"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2516.2010.02358.x","article-title":"Association between haemophilia and inherited thrombophilia: A single centre survey","volume":"17","author":"C Di Perna","year":"2011","journal-title":"Haemophilia"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.12356","article-title":"Interactions between genotype and phenotype in bleeding and thrombosis","volume":"93","author":"M Franchini","year":"2008","journal-title":"Haematologica"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2009.11.003","article-title":"Factor V Leiden and hemophilia","volume":"125","author":"M Franchini","year":"2010","journal-title":"Thromb Res"},{"issue":"02","key":"ref61","first-page":"298","article-title":"Thrombotic complications in patients with hereditary bleeding disorders","volume":"92","author":"M Franchini","year":"2004","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/14740338.2016.1208747","article-title":"The safety of pharmacologic options for the treatment of persons with hemophilia","volume":"15","author":"M Franchini","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/17474086.2017.1272410","article-title":"The current state of adverse event reporting in hemophilia","volume":"10","author":"L F van Vulpen","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"S 01","key":"ref64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000204020","article-title":"The need for highly purified products to treat hemophilia B","volume":"94","author":"I Scharrer","year":"1995","journal-title":"Acta Haematol"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","article-title":"Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies","volume":"18","author":"A Coppola","year":"2012","journal-title":"Haemophilia"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1055\/s-0033-1354425","article-title":"FEIBA versus NovoSeven in hemophilia patients with inhibitors","volume":"39","author":"M Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus FVIII bypassing activity","volume":"2","author":"L M Aledort","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues","volume":"14","author":"L M Aledort","year":"2008","journal-title":"Haemophilia"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0044-1796651","article-title":"Non-factor therapies for hemophilia: Achievements and perspectives","volume":"51","author":"V Jim\u00e9nez-Yuste","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref70","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: A narrative review","volume":"17","author":"M Franchini","year":"2019","journal-title":"Blood Transfus"},{"issue":"05","key":"ref71","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/s-0036-1571310","article-title":"Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement","volume":"42","author":"P M Mannucci","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref72","first-page":"CD014544","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2","author":"O O Olasupo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref74","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"05","key":"ref75","first-page":"1334","article-title":"Emicizumab: The hemophilia A game-changer","volume":"109","author":"P E Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"P Chowdary","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"ref77","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17474086.2023.2293096","article-title":"Efficacy\/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: A systematic review and meta-analysis","volume":"16","author":"R L Muniz","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: A closer look at fitusiran","volume":"7","author":"G Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"18","key":"ref80","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1182\/bloodadvances.2021004802C","article-title":"Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding","volume":"5","author":"M Hoffman","year":"2021","journal-title":"Blood Adv"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/bloodadvances.2024013900","article-title":"Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B","volume":"9","author":"S W Pipe","year":"2025","journal-title":"Blood Adv"},{"issue":"S 01","key":"ref86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events","volume":"136","author":"S V Seremetis","year":"2020","journal-title":"Blood"},{"issue":"09","key":"ref87","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"T Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"ref88","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): A prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"P Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"P Chowdary","year":"2020","journal-title":"Int J Hematol"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","volume":"200","author":"J N Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"J Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0044-1785483","article-title":"Gene therapy in hemophilia A: Achievements, challenges, and perspectives","volume":"51","author":"N S Bala","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"23","key":"ref94","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus-based gene therapy for hemophilia A and B: A systematic review and meta-analysis","volume":"8","author":"S R Deshpande","year":"2024","journal-title":"Blood Adv"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.rpth.2024.102673","article-title":"Adeno-associated virus-based gene therapy for hemophilia-addressing the gaps","volume":"9","author":"W Miesbach","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"08","key":"ref97","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"A D Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1055\/a-2531-4712","article-title":"Coagulation abnormalities in chronic liver disease","author":"M Franchini","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/HYPERTENSIONAHA.113.01174","article-title":"Prevalence and risk factors for hypertension in hemophilia","volume":"62","author":"A von Drygalski","year":"2013","journal-title":"Hypertension"},{"issue":"05","key":"ref100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1538-7836.2009.03318.x","article-title":"Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy","volume":"7","author":"S M Siboni","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/ejh.12134","article-title":"Renal diseases in haemophilic patients: pathogenesis and clinical management","volume":"91","author":"P Esposito","year":"2013","journal-title":"Eur J Haematol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1173549","DOI":"10.3389\/fped.2023.1173549","article-title":"Between Scylla and Charybdis: thrombosis in children with hemophilia","volume":"11","author":"J El Maamari","year":"2023","journal-title":"Front Pediatr"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2010.10.001","article-title":"Venous access in the management of hemophilia","volume":"25","author":"L A Valentino","year":"2011","journal-title":"Blood Rev"},{"issue":"06","key":"ref104","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.V98.6.1727","article-title":"Catheter-related deep venous thrombosis in children with hemophilia","volume":"98","author":"J M Journeycake","year":"2001","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2603-0344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:31:20Z","timestamp":1770766280000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2603-0344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":96,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2603-0344","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,8]]},"published":{"date-parts":[[2025,5,8]]}}}